Abstract
Background The ongoing COVID-19 pandemic is caused by the beta coronavirus SARS-CoV-2. COVID-19 manifests itself from mild or even asymptomatic infections to severe forms of life-threatening pneumonia. At the end of November 2021, yet another novel SARS-CoV-2 variant named B.1.1.529 or Omicron was discovered and classified as a variant of concern (VoC) by the WHO. Omicron shows significantly more mutations in the amino acid (aa) sequence of its spike protein than any previous variant, with the majority of those concentrated in the receptor binding domain (RBD). In this work, the binding of the Omicron RBD to the human ACE2 receptor was experimentally analyzed in comparison to the original Wuhan SARS-CoV-2 virus, and the Beta and Delta variants. Moreover, we compared the ability of human sera from COVID-19 convalescent donors and persons fully vaccinated with BNT162b2 (Corminaty) or Ad26.COV2.S (Janssen COVID-19 vaccine) as well as individuals who had boost vaccine doses with BNT162b2 or mRNA-1273 (Spikevax) to bind the different RBDs variants.
Methods The Omicron RBD with 15 aa mutations compared to the original Wuhan strain was produced baculovirus-free in insect cells. Binding of the produced Omicron RBD to hACE was analyzed by ELISA. Sera from 27 COVID-19 patients, of whom 21 were fully vaccinated and 16 booster recipients were titrated on the original Wuhan strain, Beta, Delta and Omicron RBD and compared to the first WHO Integrnational Standard for anti-SARS-CoV-2 immunoglobulin (human) using the original Wuhan strain as reference.
Results The Omicron RBD showed a slightly reduced binding to ACE2 compared to the other RBDs. The serum of COVID-19 patients, BNT162b2 vaccinated and boost vaccinated persons showed a reduced binding to Omicron RBD in comparison to the original Wuhan strain, Beta und Delta RBDs. In this assay, the boost vaccination did not improve the RBD binding when compared to the BNT162b2 fully vaccinated group. The RBD binding of the Ad26.COV2.S serum group was lower at all compared to the other groups.
Conclusions The reduced binding of human sera to Omicron RBD provides first hints that the current vaccinations using BNT162b2, mRNA-1273 and Ad26.COV2.S may be less efficient in preventing infections with the Omicron variant.
Competing Interest Statement
M.S., F.B., S.S., S.D. and M.H. are inventors on a patent application on blocking antibodies against SARS-CoV-2. S.D. and M.H. are co-founders and shareholder of CORAT Therapeutics GmbH, a company founded for clinical and regulatory development of COR-101, an antibody for the treatment of hospitalized COVID-19 patients.
Funding Statement
We kindly acknowledge the financial support of the European Union for the ATAC ("antibody therapy against corona", Horizon2020 number 101003650), the MWK Niedersachsen(14-76103-184 CORONA-2/20) for the projects "Antibody generation", "Neutralization experiments" and "Structure-based analysis of antiviral strategies against CoV-2 target proteins" and the Deutsche Herzstiftung ("Menschliche monoklonale Antikoerper gegen SARS-CoV2 zur Prophylaxe gegen COVID-19 bei vorerkrankten Risikopatienten - Unterstuetzung der Entwicklung") and the Swedisch Research Council. LCS was supported by grants from the Helmholtz Association (EU-Partering PIE-0008 and Helmholtz campaign COVIPA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was given from the ethical committee of the Technische Universitaet Braunschweig (Ethik-Kommission der Fakultaet 2 der TU Braunschweig, approval number FV-2020-02) and the approval of the Ethical Commission of Hannover Medical School (Nr. 9254_BO_K_2020). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Senior authors
Data Availability
All data produced in the present study are available upon reasonable request to the authors
